Manisha Balwani

Search results

• Mount Sinai secures $3.26m grant for new undiagnosed diseases centre

  Balwani, M. & Gelb, B.

  18/09/24

  1 item of Media coverage

  Press/Media

• Mount Sinai secures $3.26m grant for new undiagnosed diseases centre 

  Balwani, M. & Gelb, B.

  18/09/24

  1 item of Media coverage

  Press/Media

• Mount Sinai Secures $3.26M Grant for Undiagnosed Diseases Center

  Balwani, M. & Gelb, B.

  18/09/24

  1 item of Media coverage

  Press/Media

• New Four-Year, $3.26 Million Grant From the National Institute of Neurological Disorders and Stroke Establishes the Mount Sinai Center for Undiagnosed Diseases

  Balwani, M. & Gelb, B.

  17/09/24

  1 item of Media coverage

  Press/Media

• New $3.26 million grant launches Undiagnosed Diseases Network site in New York

  Balwani, M. & Gelb, B.

  17/09/24

  1 item of Media coverage

  Press/Media

• New four-year, $3.26 million grant from the National Institute of Neurological Disorders and Stroke establishes the Mount Sinai Center for Undiagnosed Diseases

  Balwani, M. & Gelb, B.

  17/09/24

  1 item of Media coverage

  Press/Media

• Investigators at Icahn School of Medicine at Mount Sinai Report Findings in Cancer Gene Therapy (Case-based Discussion of the Acute Hepatic Porphyrias: Updates On Pathogenesis, Diagnosis and Management)

  Balwani, M. & Yasuda, M.

  9/05/24

  1 item of Media coverage

  Press/Media

• Dersimelagon, an effective oral treatment for patients with erythropoietic protoporphyria: Phase 2 trial

  Balwani, M.

  7/07/23

  1 item of Media coverage

  Press/Media

• Findings from Icahn School of Medicine at Mount Sinai in RNAi-Based Therapy Reported (RNA interference therapy in Acute Hepatic Porphyrias)

  Balwani, M. & Yasuda, M.

  21/04/23

  1 item of Media coverage

  Press/Media

• Dersimelagon increases duration of symptom-free sunlight exposure in erythropoietic protoporphyria: NEJM

  Balwani, M.

  20/04/23

  1 item of Media coverage

  Press/Media

• Dersimelagon Beneficial for Erythropoietic, X-Linked Protoporphyria

  Balwani, M.

  13/04/23

  1 item of Media coverage

  Press/Media

• Dersimelagon Beneficial for Erythropoietic, X-Linked Protoporphyria; Dersimelagon at doses of 100 and 300 mg increases duration of symptom-free sunlight exposure versus placebo.

  Balwani, M.

  13/04/23

  1 item of Media coverage

  Press/Media

• Dersimelagon Beneficial for Erythropoietic, X-Linked Protoporphyria

  Balwani, M.

  13/04/23

  76 items of Media coverage

  Press/Media

• Research on Erythropoietic Protoporphyria Described by Researchers at Icahn School of Medicine at Mount Sinai (A pilot study of oral iron therapy in erythropoietic protoporphyria and X-linked protoporphyria)

  Balwani, M. & Desnick, R.

  14/12/22

  1 item of Media coverage

  Press/Media

• New COVID-19 Study Findings Reported from Icahn School of Medicine at Mount Sinai (A 51-year-old Woman With Interstitial Lung Disease and Subsequent Covid-19 Presenting With Worsening Dyspnea)

  Balwani, M.

  8/11/22

  1 item of Media coverage

  Press/Media

• Clinical Challenges: Managing Erythropoietic Protoporphyria

  Balwani, M.

  5/01/22

  1 item of Media coverage

  Press/Media

• Clinical Challenges: Treating Acute Hepatic Porphyria

  Balwani, M.

  29/12/21

  1 item of Media coverage

  Press/Media

• Clinical Challenges: Diagnosing Acute Hepatic Porphyria

  Balwani, M.

  20/12/21

  1 item of Media coverage

  Press/Media

• Givosiran Reduces Porphyria Attacks Among Patients With Acute Intermittent Porphyria

  Balwani, M.

  1/08/20

  1 item of Media coverage

  Press/Media

• Effects of Givosiran in Acute Intermittent Porphyria

  Balwani, M.

  26/06/20

  1 item of Media coverage

  Press/Media

• Givlaari lowers rate of porphyria attacks

  Balwani, M.

  11/06/20

  1 item of Media coverage

  Press/Media

• Alnylam Announces Publication Of ENVISION Phase 3 Study Results For Givosiran In The New England Journal Of Medicine

  Balwani, M.

  10/06/20

  18 items of Media coverage

  Press/Media

• Alnylam Announces Publication of ENVISION Phase 3 Study Results for Givosiran in the New England Journal of Medicine

  Balwani, M.

  10/06/20

  1 item of Media coverage

  Press/Media

• Alnylam Announces Publication of ENVISION Phase 3 Study Results for Givosiran in the New England Journal of Medicine

  Balwani, M.

  10/06/20

  1 item of Media coverage

  Press/Media

• Better outcomes of erythropoietic protoporphyria seen with afamelanotide use

  Balwani, M.

  27/03/20

  1 item of Media coverage

  Press/Media